Symmetrical drug‐related intertriginous and flexural exanthema like eruption associated with COVID‐19 vaccination

Lim, Puo Nen; Wylie, Grant

doi:10.1111/ced.14898

Cited by 18 publications

(16 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Three of five erythema multiforme cases were associated with the mRNA-1273 vaccine [ 1 , 62 , 63 ]. New onset of prurigo nodularis [ 17 ], radiation recall dermatitis [ 64 ], symmetrical drug-related intertriginous and flexural exanthema (SDRIFE)-like eruption [ 65 ], Stevens-Johnson syndrome/toxic epidermal necrolysis [ 66 , 67 , 68 ], Sweet’s syndrome [ 69 , 70 ], vitiligo [ 71 ], vasculitis [ 50 , 72 , 73 ], livedo racemosa [ 27 ], fixed drug eruption [ 27 ], pityriasis rubra pilaris-like eruption [ 74 ], and facial pustular neutrophilic eruption [ 75 ] have been reported post-vaccination. All SJS and Sweet’s syndrome cases were managed successfully.…”

Section: Resultsmentioning

confidence: 99%

Cutaneous Complications of mRNA and AZD1222 COVID-19 Vaccines: A Worldwide Review

et al. 2022

View full text Add to dashboard Cite

Because of the increasing emergence of cutaneous reactions from COVID-19 vaccines worldwide, we investigated the published reports of these complications. We searched the PubMed, Google Scholar, and Scopus databases and the preprint server bioRxiv for articles on cutaneous complications linked to mRNA-1273 (Moderna), BNT162b2 (Pfizer–BioNTech), and AZD1222 (AstraZeneca–Oxford University) vaccines published until 30 September 2021. Eighty studies describing a total of 1415 reactions were included. Cutaneous reactions were more prevalent in females (81.6%). Delayed large local reactions were the most common complication (40.4%), followed by local injection site reactions (16.5%), zoster (9.5%), and urticarial eruptions (9.0%). Injection site and delayed large local reactions were predominantly caused by the mRNA-1273 vaccine (79.5% and 72.0%, respectively). BNT162b2 vaccination was more closely linked to distant reactions (50.1%) than mRNA-1273 (30.0%). Zoster was the most common distant reaction. Of reactions with adequate information for both vaccine doses, 58.3% occurred after the first dose only, 26.9% after the second dose only, and 14.8% after both doses. Overall, a large spectrum of cutaneous reaction patterns occurred following the COVID-19 vaccination. Most were mild and without long-term health implications. Therefore, the occurrence of such dermatologic complications does not contraindicate subsequent vaccination.

show abstract

Section: Resultsmentioning

confidence: 99%

Cutaneous Complications of mRNA and AZD1222 COVID-19 Vaccines: A Worldwide Review

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Reports of COVID‐19 vaccination‐related SDRIFE are rare. 2 , 3 , 4 , 5 To date, five cases induced by an inactivated whole‐virus vaccine (CoronaVac [Sinovac Life Sciences]), messenger RNA (mRNA) vaccine (BNT162b2), and adenoviral vaccine (ChAdOx1 nCoV‐19) have been published (Table 1 ). Although it is not possible to discern the immunological mechanism of vaccine‐associated SDRIFE, it is considered a type IVc and IVd delayed‐type systemic allergic dermatitis.…”

Section: Discussionmentioning

confidence: 99%

Symmetric drug–related intertriginous and flexural exanthema–like eruption related to coronavirus disease 2019 vaccine

Hong

Shin

Yoo³

et al. 2022

Contact Dermatitis

View full text Add to dashboard Cite

received the second dose of the coronavirus disease 2019 (COVID-19) vaccine (ChAdOx1 nCoV-19 [AstraZeneca]). He denied taking any medication or supplements within 2 months before and after the second vaccination. He also denied history of any other contact or exposure. After the first injection of the COVID-19 vaccine, no adverse events occurred. Physical examination showed well-demarcated erythematous macular patches distributed symmetrically over the axillary and inguinal areas, with skin desquamation and swelling in the scrotal area and on the glans penis (Figure 1A-C). Systemic signs were absent. The blood test results were normal. Findings of direct F I G U R E 1 (A) A 53-year-old man in whom erythematous maculopatches that were distributed symmetrically over the axillary, inguinal, and perigenital areas developed 10 days after COVID-19 vaccination (ChAdOx1 nCoV-19). (B, C) Involvement of both axillary areas and the characteristic V-shaped erythema of the inguinal/perigenital area How to cite this article: Hong JK, Shin SH, Yoo KH, Li K, Seo SJ. Symmetric drug-related intertriginous and flexural exanthema-like eruption related to coronavirus disease 2019 vaccine.

show abstract

“…To our knowledge, there are only four recent reported cases of SDRIFE‐like eruption related to COVID‐19 vaccines Oxford/Astrazeneca (chAdOx1‐S Covid 19 Vaccine). 1 , 2 , 3 SDRIFE is a drug‐related type IV hypersensitivity eruption that involves the intertriginous or flexural folds and the gluteal area. It has been reported in association with beta‐lactams, antihypertensives and chemotherapeutic agents.…”

Section: Figurementioning

confidence: 99%

Symmetrical drug‐related intertriginous and flexural exanthema‐like eruption after COVID‐19 vaccine

Lahouel

Salah

Fadhel

et al. 2022

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

Symmetrical drug‐related intertriginous and flexural exanthema like eruption associated with COVID‐19 vaccination

Cited by 18 publications

References 5 publications

Cutaneous Complications of mRNA and AZD1222 COVID-19 Vaccines: A Worldwide Review

Cutaneous Complications of mRNA and AZD1222 COVID-19 Vaccines: A Worldwide Review

Symmetric drug–related intertriginous and flexural exanthema–like eruption related to coronavirus disease 2019 vaccine

Symmetrical drug‐related intertriginous and flexural exanthema‐like eruption after COVID‐19 vaccine

Contact Info

Product

Resources

About